Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Allergy Clin Immunol. 2016 Jun 11;139(2):462–471.e14. doi: 10.1016/j.jaci.2016.04.037

Fig 6.

Fig 6

IL-17A directly enhances IL-13-driven pSTAT6. pSTAT6/STAT6 levels in NIH/3T3 cells pretreated with DMSO (A) or cycloheximide (B) then stimulated with cytokines for 5 minutes, (C) densitometry of pSTAT6/STAT6 expression shown in (A,B), geometric mean fluorescence intensity of pSTAT6 by phosphoflow in NIH/3T3s stimulated with cytokines over 1 hour (D), pSTAT6 and STAT6 expression and associated densitometry in whole lung homogenates from cytokine-treated A/J mice (mean + SEM of n=7-10 mice per group, pooled from 3 independent experiments) (E), real-time PCR analysis of C3 and Il13ra2 (F) or Lcn2 (G) expression in WT and STAT6−/− lung fibroblasts stimulated with cytokines for 24 hours. #, ##, and ### indicate P<0.05, <0.01, and <0.001 vs PBS or Medium. +, ++, and +++ indicate P<0.05 , <0.01, and <0.001 vs IL-13. Cyclohexamide experiments display 1 of 3 independent experiments performed. Phosphoflow cytometry and real-time PCR results show mean + SEM of 4-6 replicates per condition shown. Results show 1 of 2 independent experiments.